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Potential protein targets of the peptidylarginine deiminase 
2 and peptidylarginine deiminase 4 enzymes in rheumatoid 
synovial tissue and its possible meaning
Introduction
Peptidylarginine deiminase (PAD) belongs to a family of calcium-dependent enzymes that convert 
arginine residues of proteins into citrulline. These enzymes are expressed in most mammalian tis-
sues, with the most common PAD2 enzyme widely distributed throughout human and murine tis-
sues (1). This isoform is responsible for the majority of PAD activity, and the importance of PAD2 has 
been demonstrated by the observation that all PAD activity is abrogated in the PAD2 knockout mouse 
(2). Protein citrullination is an important pathophysiological mechanism in rheumatoid arthritis (RA), 
which is supported by the evidence that patients with RA produce antibodies against modified cel-
lular components known as antiperinuclear factor (APF). These autoantibodies are specific to RA, and 
their immunochemical specificity is directed against filaggrin. The APF antibody was identified using 
normal epithelial cells of the oral mucosa as the antigenic source and rheumatoid serum (3-5). The 
anti-citrullinated peptide (CCP) antibodies were identified many years later and are considered as early 
markers of RA (6-10). Therefore, the importance of citrullinated epitopes in rheumatoid pathogenesis 
has continued to increase, and the molecular significance of citrullination has been tested in vitro 
using various approaches. Because of these studies, it is known that fibrinogen, vimentin, enolase, 
collagen, and other proteins are post-translationally modified (11-14) through their arginine residues 
being deiminated and transformed into citrulline. This steric change modifies the electrostatic proper-
ties of peptides, resulting in an increase in immunogenicity and changes that intensify the interaction 
of target proteins with certain pockets of Class II major histocompatibility complex (MHC) molecules 
(DR4 0401). By this mechanism, a modified protein increases its probability of being presented in a 
restricted peptide repertoire as an autoantigen (15, 16).
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Abstract
Objective: The molecular mechanism of citrullination involves the calcium-dependent peptidylarginine deiminase (PAD) family of 
enzymes. These enzymes induce a stereochemical modification of normal proteins and transform them into autoantigens, which in 
rheumatoid arthritis trigger a complex cascade of joint inflammatory events followed by chronic synovitis, pannus formation, and 
finally, cartilage destruction. By hypothesizing that PAD2 and PAD4 enzymes produce autoantigens, we investigated five possible 
synovial protein targets of PAD enzymes. 
Material and Methods: We measured PAD2, PAD4, and citrullinated proteins in 10 rheumatoid and 10 osteoarthritis synovial bi-
opsies and then assessed the post-translational modifications of fibrinogen, cytokeratin, tubulin, IgG, and vimentin proteins using 
a double-fluorescence assay with specific antibodies and an affinity-purified anti-citrullinated peptide (CCP) antibody. The degree 
of co-localization was analyzed, and statistical significance was determined by ANOVA, Fisher’s exact test, and regression analysis. 
Results: The principal results of this study demonstrated that citrullinated proteins, such as fibrinogen, IgG, and other probed pro-
teins, were targets of PAD2 and PAD4 activity in rheumatoid synovial biopsies, whereas osteoarthritis biopsies were negative for this 
enzyme (p<0.0001). An analysis of citrullination sites using the UniProtKB/Swiss-Prot data bank predicts that the secondary structure 
of the analyzed proteins displays most of the sites for citrullination; a discussion regarding its possible meaning in terms of patho-
genesis is made. 
Conclusion: Our results support the conclusion that the synovial citrullination of proteins is PAD2 and PAD4 dependent. Further-
more, there is a collection of candidate proteins that can be citrullinated.
Keywords: Peptidylarginine deiminase 2, peptidylarginine deiminase 4, rheumatoid arthritis, synovial membrane
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Considering the fact that PAD2 and PAD4 iso-
forms are overexpressed in rheumatoid sy-
novial tissue (17-20), it appears reasonable to 
infer that an antigenic stimulation may arise 
at a synovial level. Therefore, this study aimed 
to assess potential protein targets of PAD2 and 
PAD4 enzymes in rheumatoid synovial tissue. 
Material and Methods
Rheumatoid arthritis and control synovial tissue
Tissue samples were obtained during joint re-
placement for prosthesis surgery, and 10 biopsies 
from patients with a mean age of 41.2±13.1 years 
and who met the American College of Rheuma-
tology (ACR) criteria for RA classification (21) were 
analyzed. There were six females and four males 
with 10 years of evolution (range, 3–13 years), 
three with functional class (FC) III, five with II, one 
with I, and one was not defined by the ACR classi-
fication of functional status in RA (22). All patients 
were positive for rheumatoid factor and anti-CCP, 
were under treatment with a low dose of ≤5 mg 
prednisone, and received methotrexate with 
a mean dose of 12.5 mg (range, 7.5–17.5 mg). 
Additionally, 10 biopsies were obtained from 
patients with osteoarthritis (mean age, 54.2±7.1 
years), wherein six patients were females and four 
males. They were included as controls, none of 
them had anti-CCP antibodies, and one was pos-
itive for rheumatoid factor at an irrelevant con-
centration; furthermore, these patients under-
went knee surgery for osteoarthritis, all of them 
received analgesics and/or NSAIDs, and obesity 
was the accelerating factor for knee osteoarthritis 
(23, 24). In all cases, signed informed consent was 
obtained, and the bioethics committee at our in-
stitution approved this protocol. 
Purification and labeling of affinity-purified an-
ti-CCP antibodies 
An anti-CCP serum sample obtained from a pa-
tient with RA and who displayed high anti-CCP 
antibodies according to ELISA (25) was used to 
purify high-affinity antibodies in the following 
manner: serum was incubated in a commercial 
ELISA microwell plate (Axis-Shield Diagnostics 
Ltd.; Dundee, Scotland), and the anti-CCP-
bound antibodies were then eluted from the 
polystyrene CCP-coated plates after a 2-h incu-
bation with 0.2 M glycine–HCl at pH 2.8. The 
eluted antibodies were then neutralized with 1 
M Tris at pH 9.5. The recovered antibodies were 
concentrated using a Centricon® centrifugal 
device (Merck Millipore Co.; Billerica, MA, USA). 
One fraction of the high-affinity-purified an-
ti-CCP antibodies was labeled with horseradish 
peroxidase (HRP) (Sigma; St. Louis, MO, USA) 
using the method described by Abrameas 
with our own modifications. The molar ratio of 
the high-affinity-purified antibodies to peroxi-
dase was 1:10 (26, 27). Another fraction of the 
affinity-purified anti-CCP antibody was used to 
perform the double-fluorescence assays.
Immunohistochemistry 
Slides containing 4-μm sections of the syno-
vial tissue were dewaxed, permeabilized, and 
washed three times with PBS. Endogenous 
peroxidase was then blocked with horse se-
rum that had been inactivated at 56°C. The tis-
sues were incubated with purified human IgG 
(precipitated from normal human sera with 
ammonium sulfate and IgG was purified using 
HiTrap protein G HP columns) to neutralize the 
presence of possible rheumatoid factor activity 
in the synovial tissues. After three washes, the 
tissues were incubated for 1 h with the mono-
clonal antibody or affinity-purified human 
autoantibodies diluted in 10% fetal calf se-
rum/PBS (anti-citrulline antibody, cat. 231246, 
Calbiochem, Darmstadt, Germany; 1:100 dilu-
tion), anti-PAD2 antibody (PA5-19474, Pierce 
Antibody products, Thermo Fisher Scientific 
Inc.; Rockford, IL, USA; 1:30 dilution), and an-
ti-PAD4 (Pierce PA5-12236; 1:30 dilution). After 
multiple washes with PBS, the slides were then 
incubated for 1 h with HRP-labeled goat an-
ti-human IgG. After additional washes, a color 
reaction was induced using 3,3’-diaminobenzi-
dine–0.06% H2O2 (Sigma; San Louis, MO, USA), 
and the reaction was stopped with 2 N sulfuric 
acid. All assays were performed in duplicates. 
In the case of the HRP-labeled anti-CCP, the 
immunohistochemistry was direct and did not 
rely on the use of a secondary antibody.
Double-fluorescence labeling assays
To assess the presence of citrullinated pro-
tein in the synovial tissue, we co-localized the 
possible target proteins using the following 
steps. Citrullinated proteins were tagged as 
green through a 120-min incubation with an 
unlabeled and affinity-purified anti-CCP anti-
body, followed by a 120-min incubation with 
a FITC-labeled secondary antibody (ab4220 or 
ab68881, Abcam; Cambridge, MA, USA). After 
each incubation, the slides were washed three 
times with PBS. The target protein was tagged 
as red by overnight incubation with specific 
antibodies against fibrinogen (Abcam ab666), 
Table 1. PAD enzymes and citrullinated protein expression in the synovial tissues of patients 
with rheumatoid arthritis (RA) and osteoarthritis (OA) as controls
Biopsies PAD2 positive PAD4 positive CP positive Citrulline positive
RA (n=10) 10 (100%) 7 (70%) 10 (100%) 10 (100%)
OA (n=10) 0 0 0 1 (10%)
p <0.0001 <0.003 <0.0001 <0.002
CP: citrullinated proteins; PAD: peptidylarginine deiminase; RA: rheumatoid arthritis; OA: osteoarthritis
Fisher’s exact test (two tailed).
Figure 1. Detection of peptidylarginine deiminase (PAD)  expression in the synovial tissue by 
immunohistochemistry. In the coronal panels, biopsies of osteoarthritis (OA; controls) are nega-
tive. The middle panels show rheumatoid arthritis (RA) biopsies at 10× magnification. The basal 
panels show RA biopsies at 20× magnification
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cytokeratin (Sigma K8.13, Prod. C6909), IgG, 
vimentin (Cell Signaling D2H3), and β-tubu-
lin (Abcam ab21057), followed by a 120-min 
incubation with a rabbit anti-human Texas 
Red-labeled antibody (IgG-TR: sc-3920, Santa 
Cruz Biotechnology; Paso Robles, CA, USA). Fi-
nally, the slides were counterstained with DAPI, 
mounted, and evaluated under a fluorescence 
microscope using the appropriate filters for the 
dyes.
Statistical analyses 
Data were processed using the GraphPad Prism 
software (GraphPad Software Inc.; CA, USA) for 
the non-parametric assays, such as ANOVA and 
Fisher’s exact test. Regression analyses were 
performed using Pearson’s test. A p value <0.05 
was considered statistically significant.
Results
PAD2 and PAD4 expression exclusive to rheuma-
toid synovial tissues
PAD2 and/or PAD4 enzymes were expressed 
in the synovial tissues of all patients with RA 
(100%). In sharp contrast, all of the OA controls 
tested negative for these enzymes, and the 
differences between both the groups were 
significant (p<0.0001). In rheumatoid synovial 
tissue, PAD2 was expressed in the 10 biopsies 
of RA with a strong signal by immunohisto-
chemistry assays; however, PAD4 expression 
was faint, and it was present in seven synovial 
biopsies. Notably, PAD expression was detect-
able at a range of levels, particularly at the sy-
novial border and in some biopsies along the 
villi. Moreover, PAD expression was particularly 
prominent along the inflammatory infiltrates 
as well as in specific cells, such as fibroblast-like 
synoviocytes (Figure 1 and Table 1).
PAD enzymes citrullinate synovial proteins 
This study also aimed to assess whether PAD2 
enzyme could convert the residues of target 
proteins into citrulline in situ. Current results 
suggest that PAD2 and PAD4 are functional en-
zymes because they induced post-translation-
al modifications of target proteins as suggest-
ed by the immunohistochemical tag induced 
by the anti-CCP antibody. A subset of the bi-
opsies exhibited a widespread distribution of 
post-translationally modified proteins that cor-
related well with citrullinated areas that were 
identified by anti-citrulline antibodies. There-
fore, the presence of these three immunore-
agents (PAD2/PAD4, CP, and citrulline) suggests 
that the citrullination process depends on PAD 
activity, which was developed in the following 
locations: within villi, fibroblast-like cells, and 
inflammatory infiltrates (Table 2).
Table 2. Localization of PAD2 and PAD4 enzymes and citrullinated proteins (CP) in synovial of 
rheumatoid arthritis (RA) patients
RA biopsies (n=10)
Localization In villi In fibroblast-like cells In inflammatory infiltrates
PAD2 8 (80%) 2 (20%) 6 (60%)
PAD4 8 (80%) 2 (20%) 6 (60%)
CP 8 (80%) 5 (50%) 3 (30%)
CP: citrullinated proteins; PAD: peptidylarginine deiminase; RA:  rheumatoid arthritis
Figure 2. Double-fluorescence assays show the co-localization of tubulin and citrullinated pro-
tein (CP) in the synovial tissue of rheumatoid arthritis (RA). Circle of overlap cell figure in yellow 
that probably represents citrullinated tubulin. Note that tubulin is stained in red and CP in green; 
nuclei were counterstained by DAPI in blue
Figure 3. Double fluorescence of rheumatoid synovial tissue (a), the axial panel represents the 
synovial edge, the green immunofluorescence corresponds to the synovial edge, the red fluo-
rescence corresponds to the staining by an antibody reactive against citrullinated proteins, and 
the overlap picture corresponds to the merged image where the red and green fluorescence has 
a significant correlation (r=0.846) (b), the panel represents a field with an inflammatory focus of 
the same biopsy 
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Protein candidates for citrullination
To address which proteins are the targets of PAD 
activity, we screened a group of five proteins us-
ing a double-fluorescence assay and were able 
to demonstrate a good degree of co-localization 
between candidate proteins tagged in red and 
citrullinated protein domains tagged in green or 
viceversa. Such a PAD activity induces an in situ 
protein citrullination that produces a yellow color, 
and a possible catalytic reaction was expressed as 
an “r” value. The image analysis yields the follow-
ing values: IgG, 0.993±0.0; fibrinogen, 0.846±0.06; 
vimentin, 0.771±0.01; β-tubulin, 0.806±0.05; and 
cytokeratin, 0.990±0.04. The tentative citrullina-
tion areas were mainly observed in the cytoplasm; 
however, the nuclear cellular domains (blue stain-
ing by DAPI) had lower values (0.353±0.12). Con-
sequently, the differences between nuclear and 
cytoplasmic citrullination were significant with a p 
value of <0.0001 (Figure 2-4).
Discussion
This study aimed to identify the possible pro-
tein targets of PAD activity in rheumatoid sy-
novial tissue. To accomplish this goal, a dou-
ble-fluorescence approach was used to detect 
the possible protein targets of PAD2 and PAD4 
enzymes in the synovial tissues of patients 
with RA. The primary results of this study can 
be summarized as follows: 1) PAD2 and PAD4 
were exclusively detected in rheumatoid syno-
vial tissue and 2) to demonstrate whether sy-
novial PADs were functional, an anti-CCP anti-
body was purified from rheumatoid serum and 
then used in immunohistochemistry and in a 
double-fluorescence assay to co-localize can-
didate substrates for PAD, including fibrinogen, 
IgG, β-tubulin, vimentin, and cytokeratin. The 
results of this assay suggested that a variety of 
proteins suitable for citrullination are potential 
targets of PAD2 and PAD4 enzymes. 
Various attempts to disclose the possible tar-
gets of PAD activity have been proposed (28), 
and on the basis of recent data, we know that 
PAD activity may exhibit a range of substrate 
specificities. For example, PAD2 citrullinates 
β/γ-actin, whereas PAD4 citrullinates the H3 
histone. Additionally, functional PAD2 and 
PAD4 isoforms are predominantly active in 
rheumatoid synovial tissue (29-31). Further-
more, the in vitro assays demonstrated that 
fibrinogen, α-enolase, and other PAD-mod-
ified proteins become autoantigens, and 
patients with RA produce autoantibodies 
against citrullinated peptides. Notably, some 
of these citrullinated peptides can be detect-
ed in vivo in synovial fluid (30). Considering 
the aforementioned results, we assumed that 
the citrullination process occurs in rheuma-
toid synovial tissue. It is important to note 
that all these works suggest that the citrulli-
nation process is developed in the synovial 
tissue or synovial fluid, and proteins, such as 
fibrinogen or vimentin, are stereochemical-
ly modified and become potential sources 
of autoantigens (32). The main limitation of 
this study and other studies is the limited 
number of samples. Another limitation is the 
lack of association between synovial citrulli-
nated proteins and HLA-DRB1 (shared MHC 
epitope) as reported by Verpoort et al. (33); 
finally, another limitation is that most of the 
studies indirectly demonstrated citrullination 
by an anti-CCP antibody rather than directly 
elucidating the changes in protein structure 
induced by citrulline that are demonstrated 
by magnetic resonance spectroscopy (32-34).
These results confirmed synovial PAD activity, 
suggesting that this catalytic mechanism is 
important in the pathophysiology of RA. Addi-
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Figure 4. Cell-by-cell analysis of the co-localization graph of various candidate proteins for citrullina-
tion. Above, a graph of the mean and SD of correlation obtained by the co-localization of green and 
red fluorescence expressed as r-value means. The sum of these values obtained from cytoplasmic 
co-localization in individual cells was compared with the values of nuclear (DAPI) co-localization


































Figure 5. An example of sites suitable for citrullination in the fibrinogen alpha chain, which are pre-
dicted by sequence analysis of data P02671 obtained in UniProtKB/Swiss-Prot data bank. Note that 
60% of the arginine residues are located in the secondary structure
Fibrinogen alpha chain




tionally, we demonstrated that a few candidate 
targets of PAD activity were post-translationally 
modified in rheumatoid synovial tissue. Our 
results suggested that certain modified pro-
teins are potential triggers of autoimmune re-
sponses in patients with RA. Finally, taking into 
account the present results, some of the can-
didate proteins were further analyzed using 
citrullination-prediction analysis. For this pur-
pose, we used the UniProtKB/Swiss-Prot data 
bank to explore the distribution of accessible 
arginine residues in the secondary structures 
of the studied proteins. This analysis yielded 
the following results: the fibrinogen alpha 
chain displays 60% of the residues suitable for 
citrullination in its secondary structure and the 
fibrinogen beta chain displays 79% of the resi-
dues suitable for citrullination in its secondary 
structure distributed near the extreme N- and 
C-terminal ends, whereas vimentin displays 
only 42% of the residues suitable for citrullina-
tion in its secondary structure (Figure 5). 
Theoretically, the steric shift induced by citrullina-
tion affects the electrostatic properties of the can-
didate proteins. This modification consequently 
affects the structure and relaxation dynamics of 
citrullinated proteins, causing the conformation-
al modification of native proteins to produce 
neo-epitopes. Notably, this phenomenon could 
be induced by calcium-dependent reactions, 
which is the case for PAD enzymes (35, 36). 
Our results support the conclusion that the 
synovial citrullination of proteins is PAD depen-
dent. Moreover, there is a collection of candi-
date proteins that can be citrullinated, and it 
appears possible that in some patients, the 
citrullination process can be initially triggered 
in the synovial tissue. Taking into account the 
results obtained in other studies, various tis-
sues, such as the gingiva and lung, may serve 
as post-translational locations of PAD enzymes. 
Consequently, this process can occur at multi-
ple sites in the bodies of patients with RA (37-
42). Regardless of where citrullination occurs, 
the result may be similar, representing a for-
midable source of autoantigens; nevertheless, 
despite the broad range of candidates proteins 
for citrullination as suggested by current re-
sults, the most important variable to trigger 
an autoimmune response is the high-affinity 
binding of citrullinated peptides to the class II 
molecules, followed by strong co-stimulatory 
signals and the appropriate cytokine feeding. 
Therefore, we can assume that citrullination is 
an important mechanism from the pathogenic 
perspective of rheumatoid autoimmunity.
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